Melanoma & Skin Cancer

Jason J. Luke, MD, FACP, discusses the future of T-cell therapy in melanoma. 

Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation during the 2020 ASCO Direct Highlights webcast.

Alexander M. M. Eggermont, MD, PhD, discusses responses to adjuvant pembrolizumab in patients with different subtypes of stage III melanoma.

Christian U. Blank, MD, PhD, discusses adjuvant versus neoadjuvant approaches in macroscopic stage III melanoma.

Lifleucel, a TIL therapy, is being investigated in patients with metastatic melanoma.

A possible optimal sequence of radiation therapy and immune checkpoint inhibitors could help to prolong the survival of patients with melanoma who have brain metastases following surgical resection.

The neoadjuvant combination of nivolumab and ipilimumab continues to demonstrate a benefit in RFS compared with the combination given in the adjuvant setting in patients with stage III macroscopic melanoma.

The FDA has approved pembrolizumab (Keytruda) for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.